Navigation Links
Pioneer Study Urges Caution Before Adopting ICER Reviews to Determine Cost Effectiveness of Treatments
Date:1/25/2019

Review methodology could negatively impact elderly, the disabled, cancer patients and those with rare diseases

As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out the key ethical, methodological and disease-specific questions policy makers should address before deciding whether to contract with the Institute for Clinical and Economic Review (ICER) to conduct cost effectiveness reviews used to make decisions about the purchase of medicines and other medical innovations.

ICER utilizes Quality Adjusted Life Years (QALYs), a controversial evaluation technique that assigns an economic value to the longevity and quality of human life.

“The use of the QALY standard in the United Kingdom resulted in British cancer patients having some of the worst access to new cancer treatments in all of Europe and created a political crisis for British politicians,” said William Smith, author of “Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER).” “U.S. politicians may want to proceed cautiously in adopting QALYs.”

QALY is controversial because of the impact that such a methodology may have upon access to medical innovations for older Americans, the disabled, patients with cancer and patients with rare diseases.

The National Health Service (NHS) in the United Kingdom utilizes QALY metrics. But in the United States, the Affordable Care Act banned the use of QALYs for Medicare programs because of concerns about the impact upon older Americans, the disabled and the terminally ill.

Because of the vulnerability of these patient populations, Pioneer recommends that legislators avoid using ICER reviews until they are fully confident that the reviews will neither have an adverse impact upon these vulnerable populations nor discourage biopharmaceutical innovation for important unmet medical needs.

Download our one-page summary, “Key Questions for Legislators.”

About the Author

William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He has 25 years of experience in government and in corporate roles, including as vice president of public affairs and policy at Pfizer, and as a consultant to major pharmaceutical, biotechnology and medical device companies. He held senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Massachusetts Governor’s office. He is affiliated as research fellow and managing director with the Center for the Study of Statesmanship at The Catholic University of America (CUA), where he earned his PhD.

About Pioneer
Pioneer Institute is an independent, non-partisan, privately funded research organization that seeks to improve the quality of life in Massachusetts through civic discourse and intellectually rigorous, data-driven public policy solutions based on free market principles, individual liberty and responsibility, and the ideal of effective, limited and accountable government.

Read the full story at https://www.prweb.com/releases/pioneer_study_urges_caution_before_adopting_icer_reviews_to_determine_cost_effectiveness_of_treatments/prweb16056195.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Pioneers in Alzheimers research: Research couple honored for its lifetime achievement
2. 2 online science video pioneers combine to form new iBiology.org
3. Biometrics Pioneer DERMALOG Awarded German Foreign Trade Prize
4. Top 12 Pioneer Awards for seminal work in gene and cell therapy selected by blue ribbon panel
5. Pioneering path to electrical conductivity in tinker toy materials to appear in Science
6. David Allis, pioneer in epigenetics, to receive prestigious Japan Prize
7. Ronald Crystal, M.D., receives Pioneer Award
8. OU professor recognized by AAAS for pioneering efforts to advance ecological forecasting
9. Joseph Glorioso, Ph.D., receives Pioneer Award
10. Pioneer Award recipients Marina Cavazzana and Adrian Thrasher recognized for advancing gene therapy to the clinic for immunodeficiency disorders
11. Why didnt these pioneers of medicine receive a Nobel Prize?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2019)... ... 2019 , ... Orbsen Therapeutics, a biotechnology company focused on ... move its base of operations from the National University of Ireland (NUI) Galway ... in Galway, Ireland. , “With four clinical trials in full swing and the ...
(Date:4/4/2019)... ... 03, 2019 , ... R3 Stem Cell is now offering ... of Excellence. R3 wants patients to feel secure when they make a significant ... Centers that use inferior regenerative biologics, protocols or amounts, R3 provides a safe ...
(Date:3/29/2019)... (PRWEB) , ... March 28, 2019 , ... In the ... not directly prescribe a path for this task. Despite this uncertainty, several manufacturers have ... of today. In the first part of this webinar, learn how analytical similarity is ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... April 09, 2019 , ... USDM Life Sciences ... life sciences organizations to accelerate innovation and maximize productivity, announces that nearly 100 ... 12 months. , USDM’s Cloud Assurance is a managed subscription service ...
(Date:4/9/2019)... ... April 09, 2019 , ... The American Society of Gene & Cell ... team, including a new addition to the presidential line of succession, at the ... the Society's leadership team for a three-year term (2019-2021). , All five incoming members ...
(Date:4/8/2019)... ... 08, 2019 , ... US Capital Global Securities , an affiliate of ... in the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline ... hypoactive sexual dysfunction disorder and is ready to begin phase 2b trials. In phase ...
(Date:4/4/2019)... ... 2019 , ... Biomeme, Inc. , a leading manufacturer ... solution for performing PCR, RT-PCR, qPCR, and Isothermal tests called Franklin ™. ... an English chemist and X-ray crystallographer who made significant contributions to the understanding ...
Breaking Biology Technology: